Kazuki Sudo

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Peritoneal Dialysis

Metastatic Colorectal Cancer

Clinical Practice

Epidermal Growth Factor Receptor

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer research communications

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Rui Kitadai, Tatsunori Shimoi, Shu Yazaki, Hitomi Sumiyoshi Okuma, Mai Hoshino, Munehiro Ito, Ayumi Saito, Shosuke Kita, Yuki Kojima, Tadaaki Nishikawa, Kazuki Sudo, Emi Noguchi, Yasuhiro Fujiwara, Masayuki Yoshida, Kan Yonemori
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. Breast cancer (Tokyo, Japan) (2024)
Takafumi Koyama, Kan Yonemori, Toshio Shimizu, Jun Sato, Shunsuke Kondo, Kazuki Sudo, Tatsuya Yoshida, Yuki Katsuya, Tatsuki Imaizumi, Masashi Enomoto, Ryoko Seki, Noboru Yamamoto
Phase 1 study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors. Cancer research communications (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science (2024)
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, Kazuki Sudo, Makoto Hirata, Takashi Kubo, Kayoko Tao, Hourin Cho, Yoshitaka Narita, Ken Kato, Naoya Yamazaki, Yuichiro Ohe, Takuji Okusaka, Yoshiyuki Matsui, Chitose Ogawa, Kan Yonemori, Noboru Yamamoto
Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science 115 (6) (2024)
Kayoko Tao, Fumito Yamazaki, Takashi Kubo, Kuniko Sunami, Tadashi Kumamoto, Ayumu Arakawa, Masanaka Sugiyama, Yuko Watanabe, Miho Nakajima, Nami Shirakawa, Kazuki Tanimura, Takafumi Koyama, Makoto Hirata, Kazuki Sudo, Noriko Tanabe, Tomoko Watanabe, Teruhiko Yoshida, Mayuko Kitami, Akihiko Yoshida, Yasushi Yatabe, Yoshiko Nakano, Miki Ohira, Takehiko Kamijo, Atsuko Nakazawa, Motohiro Kato, Koichi Ichimura, Takashi Kohno, Noboru Yamamoto, Tomoro Hishiki, Hitotshi Ichikawa, Chitose Ogawa
Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project. JCO precision oncology 7 (2023)
Takafumi Koyama, Toshio Shimizu, Yuki Kojima, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Tatsunori Shimoi, Hitotshi Ichikawa, Shinji Kohsaka, Ryo Sadachi, Akihiro Hirakawa, Akihiko Yoshida, Reiko Makihara Ando, Toshihide Ueno, Mitsuru Yanagaki, Naoko Matsui, Kenichi Nakamura, Noboru Yamamoto, Kan Yonemori
Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study. Cancer discovery (2023)
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D Galsky, Erika Paige Hamilton, Hidetoshi Hayashi, Guy Jerusalem, Seung Tae Kim, Keun-Wook Lee, Lionel Aurelien Kankeu Fonkoua, Bradley J Monk, Danny Nguyen, Do Youn Oh, Alicia F C Okines, David M O'Malley, Paula Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, Cedric Van Marcke, Evan Y Yu, Roman Groisberg, Jorge Ramos, Sherry Tan, Thomas Eldridge Stinchcombe, Tanios S Bekaii-Saab
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Hanae Ida, Toshio Shimizu, Makoto Nishino, Yoshiaki Nakamura, Shu Yazaki, Yuki Katsuya, Jun Sato, Takafumi Koyama, Satoru Iwasa, Kazuki Sudo, Shunsuke Kondo, Kan Yonemori, Kohei Shitara, Satoshi Shiono, Daiko Matsuoka, Keisuke Yasuda, Yohei Otake, Takuya Suzuki, Takao Takase, Shuya Takashima, Kohei Yamaguchi, Taro Semba, Noboru Yamamoto
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib. Cancer research communications 3 (7) (2023)
Hanae Ida, Takafumi Koyama, Takaaki Mizuno, Kuniko Sunami, Takashi Kubo, Kazuki Sudo, Kayoko Tao, Makoto Hirata, Kan Yonemori, Ken Kato, Takuji Okusaka, Yuichiro Ohe, Yoshiyuki Matsui, Naoya Yamazaki, Chitose Ogawa, Akira Kawai, Yoshitaka Narita, Minoru Esaki, Noboru Yamamoto
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Cancer science (2022)
Shu Yazaki, Yuki Kojima, Hiroshi Yoshida, Shigemasa Takamizawa, Rui Kitadai, Tadaaki Nishikawa, Tatsunori Shimoi, Kazuki Sudo, Ayumi Saito, Hitomi Sumiyoshi Okuma, Maki Tanioka, Emi Noguchi, Masaya Uno, Mitsuya Ishikawa, Tomoyasu Kato, Yasuhiro Fujiwara, Yuichiro Ohe, Kan Yonemori
High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer. Journal of gynecologic oncology 33 (6) (2022)
Satoru Iwasa, Takafumi Koyama, Makoto Nishino, Shunsuke Kondo, Kazuki Sudo, Kan Yonemori, Tatsuya Yoshida, Kenji Tamura, Toshio Shimizu, Yutaka Fujiwara, Shigehisa Kitano, Akihiko Shimomura, Jun Sato, Fumiharu Yokoyama, Hiroyuki Iida, Maki Kondo, Noboru Yamamoto
First-in-human study of ONO-4578, an antagonist of prostaglandin E 2 receptor 4, alone and with nivolumab in solid tumors. Cancer science (2022)
Tatsunori Shimoi, Emi Noguchi, Kazuki Sudo, Yu Jo Chua, Kan Yonemori
Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (31) (2021)